Literature DB >> 17525589

Long-term effects of botulinum toxin on neuromuscular function.

Christiane G Frick1, Martina Richtsfeld, Nita D Sahani, Masao Kaneki, Manfred Blobner, J A Jeevendra Martyn.   

Abstract

BACKGROUND: Recent reports indicate increased incidence of Clostridium botulinum infections, particularly among drug abusers and tissue allograft recipients. Botulinum toxin also has potential application in biochemical warfare. The neurotoxin-induced paralysis often requires mechanical ventilation with and without muscle relaxants. The authors investigated the long-term effects of botulinum toxin on muscle function, expression of nicotinic acetylcholine receptors (nAChRs), and their interaction with muscle relaxant, atracurium.
METHODS: Rats (n=30) were injected with varying doses (0.625, 2.5, and 10 U) of botulinum toxin into the tibialis muscle. Control animals (n=9) received an equivalent volume of saline. At 128 days after injection, neuromuscular function, pharmacodynamics of atracurium, and nAChRs were evaluated.
RESULTS: Nerve-evoked tensions, including tetanic tension and muscle mass, were decreased on the toxin-injected side in a dose-dependent manner relative to saline-injected controls as well as the contralateral side. Specific muscle tension and specific tetanic muscle tension (tensions/muscle mass) were not reduced. The ED10 of atracurium was reduced, the ED50 was unchanged, and the ED90 was increased in the highest (10-U) dose of toxin group. The atracurium plasma concentration to maintain a steady state 50% paralysis was significantly reduced in the 10-U toxin group. The nAChR concentrations in the tibialis muscle were significantly increased in a dose-dependent manner in all experimental groups.
CONCLUSION: Botulinum toxin causes dose-dependent long-term neuromuscular changes. The loss of tension generating capacity is almost exclusively related to muscle atrophy, because the specific tension did not change. The decreased ED10, unaltered ED50, and increased ED90 to atracurium suggest its interactions with different isoforms of receptors having varying sensitivity to atracurium. The absence of fade, despite the persistent botulinum toxin-induced denervation (increased nAChRs), suggests that the up-regulated nAChRs may have compensated for the prejunctional effects of botulinum toxin.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17525589     DOI: 10.1097/01.anes.0000267597.65120.16

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  12 in total

1.  A single injection of botulinum toxin decreases the margin of safety of neurotransmission at local and distant sites.

Authors:  Christiane G Frick; Heidrun Fink; Manfred Blobner; Jeevendra Martyn
Journal:  Anesth Analg       Date:  2011-10-14       Impact factor: 5.108

Review 2.  Biotoxins in muscle regeneration research.

Authors:  Mohamed A A Mahdy
Journal:  J Muscle Res Cell Motil       Date:  2019-07-29       Impact factor: 2.698

3.  Train-of-four and tetanic fade are not always a prejunctional phenomenon as evaluated by toxins having highly specific pre- and postjunctional actions.

Authors:  Michio Nagashima; Shingo Yasuhara; J A Jeevendra Martyn
Journal:  Anesth Analg       Date:  2013-03-11       Impact factor: 5.108

4.  Comparison of botulinum toxin type A and aprotinin monotherapy with combination therapy in healing of burn wounds in an animal model.

Authors:  Ahmad Oryan; Esmat Alemzadeh
Journal:  Mol Biol Rep       Date:  2020-03-07       Impact factor: 2.316

5.  Hyperspasticity After Partial Neurectomy for Treatment of Myospasms Following Subpectoral Breast Reconstruction.

Authors:  Frederik P Mamsen; Lena F Carstensen
Journal:  Plast Reconstr Surg Glob Open       Date:  2019-05-21

6.  Comparison of botulinum toxin with surgery for the treatment of acute acquired comitant esotropia and its clinical characteristics.

Authors:  Li-Juan Lang; Yu Zhu; Zhi-Gang Li; Guang-Ying Zheng; Hai-Ying Peng; Jun-Bo Rong; Li-Min Xu
Journal:  Sci Rep       Date:  2019-09-25       Impact factor: 4.379

7.  Treatment of acute acquired concomitant esotropia.

Authors:  Minghua Shi; Yuanxiang Zhou; Aijiao Qin; Jing Cheng; Hongxing Ren
Journal:  BMC Ophthalmol       Date:  2021-01-06       Impact factor: 2.209

8.  Recombinant botulinum neurotoxin serotype A1 in vivo characterization.

Authors:  Cindy Périer; Vincent Martin; Sylvie Cornet; Christine Favre-Guilmard; Marie-Noelle Rocher; Julien Bindler; Stéphanie Wagner; Emile Andriambeloson; Brian Rudkin; Rudy Marty; Alban Vignaud; Matthew Beard; Stephane Lezmi; Mikhail Kalinichev
Journal:  Pharmacol Res Perspect       Date:  2021-10

Review 9.  Insights on the trafficking and retro-translocation of glycosphingolipid-binding bacterial toxins.

Authors:  Jin A Cho; Daniel J-F Chinnapen; Emil Aamar; Yvonne M te Welscher; Wayne I Lencer; Ramiro Massol
Journal:  Front Cell Infect Microbiol       Date:  2012-04-11       Impact factor: 5.293

Review 10.  Molecular mechanisms of treadmill therapy on neuromuscular atrophy induced via botulinum toxin A.

Authors:  Sen-Wei Tsai; Hsiao-Ling Chen; Yi-Chun Chang; Chuan-Mu Chen
Journal:  Neural Plast       Date:  2013-11-12       Impact factor: 3.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.